VTRSViatris Inc.

$17B

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.7B+5.0% YoY

Gross Profit

$1.1B30.6% margin

Operating Income

-$266M-7.2% margin

Net Income

-$340M-9.2% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

-1.5%

Cash Flow

Operating Cash Flow

$816M

Free Cash Flow

$551M

Stock-Based Comp.

$49M

Balance Sheet

Total Assets

$37.2B

Total Liabilities

$22.5B

Stockholders' Equity

$14.7B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.7B	$3.5B	+5.0%
Gross Profit	$1.1B	$1.2B	-6.6%
Operating Income	-$266M	-$180M	-47.7%
Net Income	-$340M	-$517M	+34.2%

Revenue Segments

Brands

$2.3B64%

Generics

$1.3B36%

Geographic Segments

Developed Markets Segment

$2.3B61%

Greater China Segment

$573M15%

Emerging Markets Segment

$566M15%

Japan, Australia and New Zealand Segment

$307M8%

VTRS Q4 2025 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena